Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan
Last Updated: Friday, August 18, 2023
A retrospective study of 408 cases involving patients who received tisa-cel for treatment of DLBCL found manufacturing failure in 7.4% of patients. Repeated and short washout periods for bendamustine contributed to the risk of manufacturing failure.
Advertisement
News & Literature Highlights